Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05799118 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of the Role of Genetic Modifiers in Hemoglobinopathies

Study acronym: INHERENT
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study sites: 24 to 26v4
  2. Study sites: 25 to 24v3
  3. Re-verified, no change to tracked fieldsv2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study will investigate the role of genetic modifiers in hemoglobinopathies through a large-scale, multi-ethnic genome-wide association study (GWAS).
Trial Details
NCT Number NCT05799118
Lead Sponsor Cyprus Institute of Neurology and Genetics
Conditions
(from sponsor)		 Sickle Cell Disease, Thalassemia, Beta, Thalassemia Alpha, Hemoglobinopathies
Related terms alpha-Thalassemia, Anemia, Sickle Cell, beta-Thalassemia, Hemoglobinopathies, Thalassemia
Enrollment 30,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov